Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

BACKGROUND: SCLC has limited treatment options and inadequate preclinical models. Promising activity of arsenic trioxide (ASO) recorded in conventional preclinical models of SCLC supported the clinical evaluation of ASO in patients. We assessed the efficacy of ASO in relapsed SCLC patients and in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Owonikoko, Taofeek K., Zhang, Guojing, Kim, Hyun S., Stinson, Renea M., Bechara, Rabih, Zhang, Chao, Chen, Zhengjia, Saba, Nabil F., Pakkala, Suchita, Pillai, Rathi, Deng, Xingming, Sun, Shi-Yong, Rossi, Michael R., Sica, Gabriel L., Ramalingam, Suresh S., Khuri, Fadlo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855771/
https://www.ncbi.nlm.nih.gov/pubmed/27142472
http://dx.doi.org/10.1186/s12967-016-0861-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855771/
https://www.ncbi.nlm.nih.gov/pubmed/27142472
http://dx.doi.org/10.1186/s12967-016-0861-5

Ejemplares similares